Acute Ischemic Stroke Clinical Trial
Official title:
Impact of a Standardized Alarming System on Treatment Times and Workflow in Stroke Patients With Interhospital Transfer for Thrombectomy
NCT number | NCT05963685 |
Other study ID # | MT-ALARM |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | September 16, 2022 |
Est. completion date | March 15, 2024 |
The aim of this study is to evaluate the impact of a standardized alarming system on treatment times and workflow in stroke patients with interhospital transfer for mechanical thrombectomy (MT). The main questions it aims to answer are: - Is the implementation of a standardized alarming system associated with shorter transfer and treatment times? - Is the implementation of a standardized alarming system associated with a better adherence on existing standard operating procedures for interhospital transfer? We will analyze data from our existing thrombectomy registry comparing time periods before and after introduction of the MT alarming system.
Status | Recruiting |
Enrollment | 280 |
Est. completion date | March 15, 2024 |
Est. primary completion date | March 15, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - age >= 18 years - diagnosis of acute ischemic stroke - indication for mechanical thrombectomy - admission to one of 7 participating primary stroke centers within in the catchment area of the referral center Exclusion Criteria: - unclear indication for mechanical thrombectomy (patients admitted for perfusion imaging before decision for or against a MT) |
Country | Name | City | State |
---|---|---|---|
Germany | Munich Municipal Hospital | Munich | Bavaria |
Lead Sponsor | Collaborator |
---|---|
Munich Municipal Hospital |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | decision-to-groin time | time from decision for MT (while patient still in the primary stroke center) to groin puncture (start of mechanical thrombectomy procedure in the primary thrombectomy center) | 24 hours | |
Secondary | decision-to-departure time | time from decision for MT to departure of the patient from primary stroke center (to the primary thrombectomy center) | 24 hours | |
Secondary | decision-to-arrival time | time from decision for MT to arrival of the patient at the primary thrombectomy center | 24 hours | |
Secondary | arrival-to-groin time | time from arrival of the patient at the primary thrombectomy center to groin puncture (start of mechanical thrombectomy procedure) | 24 hours | |
Secondary | rate of refusal of transfer requests due to lack of capacity | rate of patients that had to be transferred to a secondary thrombectomy center instead of the primary thrombectomy centre due to lack of capacity in the referral clinic | 24 hours | |
Secondary | decision-to-transfer request time | Time from decision for MT to request of emergency medical service for interhospital transfer | 24 hours | |
Secondary | Periprocedural complications | rate of periprocedural complications during MT | 24 hours | |
Secondary | Successful outcome of MT (mTICI > 2b) | rate of successfully performed MT (mTICI > 2b) of all patients with attempted MT | 24 hours | |
Secondary | groin-to-recanalization time | Time from groin puncture to successful recanalization | 24 hours | |
Secondary | Adverse events within 7 days | Adverse events within the first 7 days after transfer to referral center | 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT06437431 -
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 |